SEC Form 4 · accession 0001437749-17-003889
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Edwardson
Officer — Chief Operations Officer
Period of report
Feb 24, 2017
Accepted (ET)
Mar 6, 2017 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 24, 2017 | A | 6,968 | $0.00 | A | 54,194 | D | |
| Ordinary SharesF1 | Mar 3, 2017 | S | 5,923 | $14.9219 | D | 48,271 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3 | $13.50 | Feb 24, 2017 | A | 31,650 | A | — | Feb 24, 2027 | Ordinary Shares | 31,650 | 31,650 | D |
Explanation of responses
- F1The price reported for the sales on March 3, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.86 to $15.00 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- F2Option granted under Issuer's 2013 Share Incentive Plan.
- F3Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2018 through January 1, 2021.